Objective Infliximab, a monoclonal antibody against tumor necrosis factor α, is approved by
the US Food and Drug Administration for treatment of numerous autoimmune disorders. We …

Objective To establish the safety and efficacy of infliximab for the treatment of refractory
noninfectious uveitis. Design Retrospective, interventional, noncomparative cohort study …

Objective To report the outcomes of infliximab therapy in the treatment of ocular
inflammatory disease refractory to traditional immunomodulatory therapy (IMT). Methods We …

Anti-tumour necrosis factor (TNF) molecules have become a valuable addition to the
therapeutic armamentarium for patients with severe uveitis. 1– 7 A retrospective study was …

OBJECTIVE: Uveitis in children most commonly is associated with juvenile idiopathic
arthritis. In addition to topical glucocorticoids, treatment may include systemic …

Objective: Infliximab is a chimeric antibody which binds tumor necrosis factor (TNF). It is
effective in several chronic inflammatory conditions, including sarcoidosis. Methods: We …

Objective To analyze the factors associated with response to anti–tumor necrosis factor (anti‐
TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab …

PURPOSE: To assess the response and adverse events associated with infliximab treatment
for refractory, noninfectious pediatric uveitis. DESIGN: Retrospective noncomparative case …

PURPOSE: Anti–tumor necrosis factor α (anti–TNF-α) agents are being used increasingly in
refractory inflammatory eye diseases. We reviewed our patients on etanercept and infliximab …

OBJECTIVE: To assess the efficacy and safety of the anti–tumor necrosis factor α agent
infliximab in treatment-resistant uveitis and scleritis. DESIGN: Retrospective …